Adial Pharmaceuticals, Inc. Business Acquisition, Pro Forma Earnings Per Share, Diluted
Adial Pharmaceuticals, Inc. (ADIL) reported Business Acquisition, Pro Forma Earnings Per Share, Diluted of -$1.05 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-30.
Discontinued › Income Statement › Earnings Per Share
us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted · last filed 2023-03-30
- Adial Pharmaceuticals, Inc. business acquisition, pro forma earnings per share, diluted for fiscal 2021 was -$1.05.
| Period end | Business Acquisition, Pro Forma Earnings Per Share, Diluted 12 month |
|---|---|
| 2021-12-31 | -$1.05 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |